157 related articles for article (PubMed ID: 26536456)
61. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
62. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming.
Jin J; Qiu S; Wang P; Liang X; Huang F; Wu H; Zhang B; Zhang W; Tian X; Xu R; Shi H; Wu X
J Exp Clin Cancer Res; 2019 Aug; 38(1):377. PubMed ID: 31455352
[TBL] [Abstract][Full Text] [Related]
63. Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway.
Yu M; Li H; Liu Q; Liu F; Tang L; Li C; Yuan Y; Zhan Y; Xu W; Li W; Chen H; Ge C; Wang J; Yang X
Cell Signal; 2011 May; 23(5):883-92. PubMed ID: 21262351
[TBL] [Abstract][Full Text] [Related]
64. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
65. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
[TBL] [Abstract][Full Text] [Related]
66. Severe Fever with Thrombocytopenia Syndrome Virus NSs Interacts with TRIM21 To Activate the p62-Keap1-Nrf2 Pathway.
Choi Y; Jiang Z; Shin WJ; Jung JU
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852783
[TBL] [Abstract][Full Text] [Related]
67. Nuclear factor E2-related factor 2-dependent myocardiac cytoprotection against oxidative and electrophilic stress.
Zhu H; Jia Z; Misra BR; Zhang L; Cao Z; Yamamoto M; Trush MA; Misra HP; Li Y
Cardiovasc Toxicol; 2008; 8(2):71-85. PubMed ID: 18463988
[TBL] [Abstract][Full Text] [Related]
68. Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Soliman KFA
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432484
[TBL] [Abstract][Full Text] [Related]
69. Discovery of potent, novel Nrf2 inducers via quantum modeling, virtual screening, and in vitro experimental validation.
Williamson TP; Amirahmadi S; Joshi G; Kaludov NK; Martinov MN; Johnson DA; Johnson JA
Chem Biol Drug Des; 2012 Dec; 80(6):810-20. PubMed ID: 22925725
[TBL] [Abstract][Full Text] [Related]
70. A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells.
Tang YC; Chang HH; Chen HH; Yao JY; Chen YT; Chuang YJ; Chang JY; Kuo CC
J Food Drug Anal; 2021 Dec; 29(4):638-652. PubMed ID: 35649133
[TBL] [Abstract][Full Text] [Related]
71. Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
Chepikova OE; Malin D; Strekalova E; Lukasheva EV; Zamyatnin AA; Cryns VL
Breast Cancer Res Treat; 2020 Oct; 183(3):549-564. PubMed ID: 32696316
[TBL] [Abstract][Full Text] [Related]
72. Endogenous production of ω-3 polyunsaturated fatty acids mitigates cisplatin-induced myelosuppression by regulating NRF2-MDM2-p53 signaling pathway.
Xu Q; Zhang Z; Tang M; Xing C; Chen H; Zheng K; Zhao Z; Zhou S; Zhao AZ; Li F; Mu Y
Free Radic Biol Med; 2023 May; 201():14-25. PubMed ID: 36906190
[TBL] [Abstract][Full Text] [Related]
73. Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients.
Gruosso T; Mieulet V; Cardon M; Bourachot B; Kieffer Y; Devun F; Dubois T; Dutreix M; Vincent-Salomon A; Miller KM; Mechta-Grigoriou F
EMBO Mol Med; 2016 May; 8(5):527-49. PubMed ID: 27006338
[TBL] [Abstract][Full Text] [Related]
74. Nitroalkene fatty acids mediate activation of Nrf2/ARE-dependent and PPARγ-dependent transcription by distinct signaling pathways and with significantly different potencies.
Bates DJ; Smitherman PK; Townsend AJ; King SB; Morrow CS
Biochemistry; 2011 Sep; 50(36):7765-73. PubMed ID: 21827153
[TBL] [Abstract][Full Text] [Related]
75. Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.
Stern S; Liang D; Li L; Kurian R; Lynch C; Sakamuru S; Heyward S; Zhang J; Kareem KA; Chun YW; Huang R; Xia M; Hong CC; Xue F; Wang H
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35579950
[TBL] [Abstract][Full Text] [Related]
76. [Down-regulation of Nrf2-ARE signaling pathway].
Wang XJ; Wu JG; Tang XW
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 39(1):1-5. PubMed ID: 20175228
[No Abstract] [Full Text] [Related]
77. Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway.
Li J; Zhang J; Zhu Y; Afolabi LO; Chen L; Feng X
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175972
[TBL] [Abstract][Full Text] [Related]
78. Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor:
Beeraka NM; Zhang J; Zhao D; Liu J; A U C; Vikram Pr H; Shivaprakash P; Bannimath N; Manogaran P; Sinelnikov MY; Bannimath G; Fan R
Curr Pharm Des; 2023; 29(30):2408-2425. PubMed ID: 37861038
[TBL] [Abstract][Full Text] [Related]
79. Nuclear localization of NRF2 in stroma of HER2 positive and triple-negative breast cancer.
Orešić T; Bubanović S; Ramić S; Šarčević B; Čipak Gašparović A
Pathol Res Pract; 2023 Aug; 248():154662. PubMed ID: 37421843
[TBL] [Abstract][Full Text] [Related]
80. NRF2 signaling pathway: A comprehensive prognostic and gene expression profile analysis in breast cancer.
Soghli N; Yousefi H; Naderi T; Fallah A; Moshksar A; Darbeheshti F; Vittori C; Delavar MR; Zare A; Rad HS; Kazemi A; Bitaraf A; Hussen BM; Taheri M; Jamali E
Pathol Res Pract; 2023 Mar; 243():154341. PubMed ID: 36739754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
